- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00884702
Regional Rates of Cerebral Protein Synthesis: Effects of Sleep and Memory Consolidation
Background:
- The brain needs sleep to function normally, but the purpose of sleep is not understood. Brain activity decreases during sleep, so it may be that sleep is important to maintain, repair, or reorganize brain cells. In animals, the formation of brain proteins increases during sleep, and the same thing may happen in humans.
- There is also evidence that learning and memory are helped by sleep, and that the synthesis of proteins in the brain are involved.
Objectives:
- To examine the formation of proteins in the brain while people are awake, deprived of sleep, and during sleep.
- To look at the formation of proteins in the brain while awake or asleep and following learning a task.
Eligibility:
- Healthy volunteers between 18 and 28 years of age.
- Volunteers must not have psychiatric, neurologic, or sleep disorders or certain types of vision problems, and must be able to undergo imaging studies.
Design:
- Study Part I (protein formation in waking, sleep deprivation, and sleep):
- Participants will wear an actigraph (a unit to record motor activity) for 2 weeks prior to admission.
- Participants will have physical and psychological examinations, along with a blood sample.
- After admission participants will have three positron emission tomography (PET) scans to study protein formation and one magnetic resonance imaging (MRI) scan over the course of two days.
- Participants may be asked to stay awake for as long as 20 hours and will be monitored throughout.
- Participants will be able to sleep overnight after they complete the required scans and monitoring, and will be discharged the following morning.
- Study Part II (protein formation in waking and sleep combined with a learning task):
- Participants will wear an actigraph (a unit to record motor activity) for 2 weeks prior to admission.
- Participants will have physical and psychological examinations, along with a blood sample.
- After admission participants may be asked to stay awake for as long as 20 hours and will be monitored throughout.
- The next morning, participants will be trained to perform a computerized visual discrimination task, and will be tested 8 hours later (after sleep or after remaining awake) on the visual discrimination task.
- Some participants may have PET and MRI scans as part of the study.
- Participants will be able to sleep overnight after they complete the required tests and scans, and will be discharged the following morning.
- Participants will receive financial compensation for their participation in these studies.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
Maryland
-
Bethesda, Maryland, Stati Uniti, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
- INCLUSION CRITERIA:
Healthy male and female volunteers who have no present or past diagnosis of neurologic, medical or psychiatric conditions which may confound either learning trails, normal sleep patterns or the ability to undergo sleep deprivation.
Healthy male and female subjects, 18-28 years of age, who do not meet any exclusion criteria, with self-reported normal sleep patterns (i.e., 6-9 h per night) and no major sleep disruptions during the four weeks prior to evaluation will be considered for inclusion in the study.
EXCLUSION CRITERIA INCLUDE A HISTORY OF, OR CURRENT:
- chronic medical condition which is a contraindication for PET or MRI scanning,
- past or present diagnosis of psychiatric conditions (DSM-IV criteria) (many conditions (e.g. depression), may confound performance on learning trails or be associated with baseline sleep abnormalities),
- chronic/degenerative/acquired neurologic disorder, (4) family history of genetically transmissible neurologic disorder,
(5) sleep disorders or medical conditions associated with chronically disordered sleep which may confound performance on learning trails or interfere with the sleep requirements of this study,
(6) visual impairments which may confound performance on learning trails,
(7) claustrophobic subjects,
(8) subjects who meet the above inclusion criteria, but are unable to cooperate with the requirements of the study (e.g. refusal to wear actigraphs or maintain 10 hours time in bed, reported difficulty sleeping away from home or on their backs).
(9) Subjects with chronic indicated or non-indicated use of any medications which interfere with sleep architecture and/or learning trails will be excluded. Generally, we will prohibit the use of medications/agents (e.g. anti-histamines, benadryl, melatonin, cigarettes, chocolate, coffee, tea, caffeine drinks etc.), which have significant CNS penetration, are alerting, and/or disrupt physiologic sleep-wake cycles or sleep architecture, for the 72 hrs immediately preceding presentation for the study. To acclimatize subjects, we will encourage patients to discontinue or minimize the use of these agents/medications (e.g. less than or equal to 1 cup of coffee/day) at the time of initial screening (at the same time as actigraphy application, approximately 2 wks prior to the study).
Similarly, we ask subjects to minimize alcohol use for the 2 wks prior to the study and will discontinue alcohol use for the 72 hrs immediately preceding the study.
(10) Subjects who have used illicit drugs (marijuana, cocaine, heroin, etc.) within the immediate 2 wks preceding the study.
(11) Female subjects will be excluded if either clinical history is suspicious for, or laboratory evaluation is consistent with pregnancy.
(12) Subjects unwilling to undergo HIV testing, unless enrolling in Part IIa of the study.
(13) Subjects who test HIV positive.
(14) Patients with para- and/or ferro-magnetic prosthesis/implants/fragments in their body will be excluded from the study.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
---|---|
Regional rates of cerebral protein synthesis
Lasso di tempo: 48 hrs
|
48 hrs
|
Misure di risultato secondarie
Misura del risultato |
Lasso di tempo |
---|---|
Sleep state and performance on visual discrimination task.
Lasso di tempo: 48 hrs
|
48 hrs
|
Collaboratori e investigatori
Investigatori
- Investigatore principale: Carolyn B Smith, Ph.D., National Institute of Mental Health (NIMH)
Pubblicazioni e link utili
Pubblicazioni generali
- Armitage R. Microarchitectural findings in sleep EEG in depression: diagnostic implications. Biol Psychiatry. 1995 Jan 15;37(2):72-84. doi: 10.1016/0006-3223(94)00082-E.
- Bishu S, Schmidt KC, Burlin T, Channing M, Conant S, Huang T, Liu ZH, Qin M, Unterman A, Xia Z, Zametkin A, Herscovitch P, Smith CB. Regional rates of cerebral protein synthesis measured with L-[1-11C]leucine and PET in conscious, young adult men: normal values, variability, and reproducibility. J Cereb Blood Flow Metab. 2008 Aug;28(8):1502-13. doi: 10.1038/jcbfm.2008.43. Epub 2008 May 21.
- Boyle PJ, Scott JC, Krentz AJ, Nagy RJ, Comstock E, Hoffman C. Diminished brain glucose metabolism is a significant determinant for falling rates of systemic glucose utilization during sleep in normal humans. J Clin Invest. 1994 Feb;93(2):529-35. doi: 10.1172/JCI117003.
- McWhirter KK, Morrow AS, Lee BA, Bishu S, Zametkin AJ, Balkin TJ, Smith CB, Picchioni D. A PILOT STUDY ON THE ENCODING OF A PERCEPTUAL LEARNING TASK FOLLOWING SLEEP DEPRIVATION. Percept Mot Skills. 2015 Aug;121(1):80-93. doi: 10.2466/23.PMS.121c11x9. Epub 2015 Jul 30.
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Altri numeri di identificazione dello studio
- 090123
- 09-M-0123
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Mappatura del cervello
-
University of PadovaCompletatoPropofol | Anestesia Brain MonitoringItalia
-
University of PadovaCompletato
-
University of PadovaReclutamentoAnestesia Brain MonitoringItalia
-
University of PadovaCompletato
-
Texas Christian UniversityCompletatoMapping Enhanced Counseling (MEC) | Collegamento attivo (AL)Stati Uniti
-
University of PadovaCompletato
-
University of PadovaCompletatoPropofol | Anestesia Brain MonitoringItalia
-
University of PadovaCompletatoLidocaina | Anestesia Brain MonitoringItalia
-
University of Dublin, Trinity CollegeSconosciutoBrain Health Atleti d'élite in pensione
-
Assiut UniversityCompletatoMorfometria basata su Brain Voxel in ManiaEgitto